Kirsty is biosimiler to Novolog. It is a rapid-acting human insulin analog indicated to improve glycemic control in adults ...

The report includes historical data from 2023 to 2024 and forecasts until 2033. The insulin pen market in the United States has experienced remarkable growth over the last few years.

The insulin discovery we forgot.Editorial Policies Community standards Republishing guidelines Friends of The Conversation Analytics Our feeds Donate Get newsletter Who we are Our charter Our team ...

The insulin pens market is witnessing significant growth due to the increasing prevalence of diabetes worldwide and the rising preference for advanced, user-friendly insulin delivery systems. Insulin ...

Insulin pens don't eliminate your need to poke yourself with a needle. Here's what you need to know about insulin pens.

The global Smart Insulin Pens Market is experiencing substantial growth, driven by the increasing prevalence of diabetes, advancements in digital healthcare solutions, and the demand for user-friendly ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes injections.

As sales of Novo Nordisk’s GLP-1 drugs for diabetes and obesity continue to soar, the Danish drugmaker is once again adjusting its insulin production priorities. | Citing "capacity constraints ...

Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin pens to $1 per device in low- and middle-income countries (LMICs). Pens ...